Current Controversies in the Pharmacological Treatment of COPD - the role of LABA/LAMA and ICS/LABA/LAMA inhalers
These meetings are intended for UK Healthcare Professionals and have been developed in accordance with the ABPI Code of Practice.
PM Healthcare events are Quality Assured by the University of Bradford
| Satellite | Current Controversies in the Pharmacological Treatment of COPD - the role of LABA/LAMA and ICS/LABA/LAMA inhalers | |||
| Speakers | Professor Dave Singh, Professor of Clinical Pharmacology and Respiratory Medicine, University Hospital Of South Manchester NHS Foundation Trust | |||
| Satellite Description | ||||
|
This sponsored session is organised and funded by Chiesi Ltd The evidence base for the role of combination inhalers in COPD is rapidly evolving. Dual bronchodilators, containing a long acting muscarinic antagonist and long acting beta agonist (LAMA/LABA combinations) improve symptoms and quality of life. These bronchodilator combinations also prevent exacerbations, and one study showed superior efficacy for exacerbation prevention compared to an inhaled corticosteroid (ICS) / LABA combination in patients at high risk of exacerbations. These studies have changed the shape of COPD guidelines, placing a greater emphasis on using LAMA/LABA combinations. Recent studies have shown clinical efficacy for single inhaler triple therapies (ICS/LABA/LAMA). These inhalers provide a potentially simpler option for many patients. An individualised approach is needed in COPD, with stepwise treatment that results in the optimum use of combination inhalers. | ||||
| Sponsored By | Chiesi Ltd | |||
